Global /India /Healthcare /Drug Manufacturers - General /540686
chevron_leftBack
Smruthi Organics Ltd. logo

Smruthi Organics Ltd.

540686
BSE: 540686 Delayed
111.84INR 0.3%
1.18 USD
As of 20 June 2026, Smruthi Organics Ltd. has a market cap of $13.56M USD, ranking #39619 globally and #3008 in India. It ranks #3536 in the Healthcare sector, and #1155 in the Drug Manufacturers - General industry.
Global Rank
39619
Country Rank
3008
Sector Rank
3536
Industry Rank
1155
Key Stats
Market Cap
$13.56MUSD
1.28B INR
Enterprise Value
$14.42MUSD
1.36B INR
Revenue (TTM)
$11.76MUSD
1.11B INR
EBITDA (TTM)
$1.4MUSD
132.21M INR
Net Income (TTM)
$486.18KUSD
45.89M INR
EBITDA Margin
12%
Profit Margin
4.1%
PE Ratio
27.8
PS Ratio
1.2
PB Ratio
1.8
EV/EBITDA
10.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Purushotham Eaga open_in_new
Employees
267
Founded
1989
Website
smruthiorganics.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.3% -2.2% 4.3% -5.1% -14% -1.5%

News

Loading...

Markets

Exchange Ticker Price
Bombay Stock Exchange
MIC: XBOM
PRIMARY
540686 (SMRUTHIORG)
Smruthi Organics Ltd
ISIN: INE172E01011
Shares Out.:
11.446M1 Shares Float: 8.705M2
TV:
SA:
YF:
GF:
BA:
MS:
111.84 INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Smruthi Organics Ltd.

Smruthi Organics Limited manufactures and markets active pharmaceutical ingredient (API) products to India. The company provides API for cardiovascular that includes amlodipine besilate, losartan potassium, telmisartan, s - amlodipine besilate, s - amlodipine malelate, and valsartan; for anti diabetic, which comprises metformin HCL, vildagliptin, teneligliptin, and dapagliflozin; and for anti infectives that consists of ciprofloxacin HCL, diloxanide furoate, norfloxacin, and pefloxacin mesylate, as well as ticagrelor for anti platelets. It also offers drug intermediates, such as amlodipine base, s-amlodipine base, and phthaloyl amlodipine. In addition, the company is developing empagliflozin for anti-diabetics; and apixaban and rivaroxaban for anti-platelets. It also exports its products. The company was incorporated in 1989 and is headquartered in Solapur, India.

Similar Companies

Industry: Drug Manufacturers - General (India)
Name
Market Cap diff.
PE
$45.22B
4.27T INR
333K%
39.1
DIVISLAB
$18.38B
1.73T INR
135K%
70.0
$15.17B
1.43T INR
112K%
63.0
$11.73B
1.11T INR
86K%
19.6
MANKIND
$9.87B
931.67B INR
73K%
52.2
ZYDUSLIFE
$9.71B
916.53B INR
71K%
18.6
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
6M%
38.1
JNJ
$547.28B
4M%
26.4
ABBV
$360.63B
3M%
97.4
$318.3B
256.25B CHF
2M%
19.9
AZN
$284.64B
215.59B GBP
2M%
27.6
MRK
$274.03B
2M%
15.1
chevron_leftBack